| TME Pharma | |
| Type: | Aktiengesellschaft |
| Key People: |
|
| Num Employees: | 10 (2017)[1] |
| Foundation: | 1997 |
| Location: | Berlin, Germany |
| Homepage: | www.tmepharma.com |
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers,[2] from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.[3]
Some Spiegelmer candidates were in clinical trials.
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[4]
A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive diabetic nephropathy. Favorable results were reported in June 2014 in a company press release.[5] NOX-E36 targets MCP-1, also called CCL2.[3] A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of anemia of chronic disease.[6]